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Summary 
Given the continued global burden of tuberculosis (TB), with an estimated 9.1 
million new infections and 1.5 million TB related deaths in 2006, there is a pressing 
need to develop novel and more effective anti-TB drugs. Experience of the last few 
years shows that even with the availability of the genome sequence of the disease 
causing organism, Mycobacterium tuberculosis, and new technologies in drug 
discovery, it remains difficult to identify novel TB drug targets and compounds based 
solely on genetic validation. Therefore, in vivo testing of tool compounds needs to be 
incorporated early in the drug discovery process. 
Here we set out to identify potential host lipid biomarkers in mice. Such 
biomarkers might be used as a non-lethal drug efficacy read-out for the TB mouse 
models, to replace the currently used methods, which are slow, lethal and laborious. 
For this purpose, we conducted a mouse experiment with three groups 
(healthy, infected, cured). Lipids were extracted from whole blood and analyzed using 
a systems scale approach called lipidomics, which is based on electrospray ionization 
mass spectrometry. Using conventional statistics, we were able to identify twelve 
lipid biomarkers, which were up or down regulated during infection and reverted to 
the healthy state upon rifampicin treatment. Interestingly, the list of these biomarker 
lipids included mainly phosphatidylserines and phosphatidylcholines. 
We also successfully used our lipid data to train support vector machine 
(SVM) based models, which were then able to differentiate between diseased and 
non-diseased mice. 
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1.1. Tuberculosis 
1.1.1. Global Burden 
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is an ancient 
human disease. The ability to diagnose TB by acid-fast-bacillus smear and the 
discovery of several effective drugs in the 1940s lead to a significant decrease in TB 
incidence in the middle of the last century. By the 1980s, the disease was believed to 
be conquered (Harries and Dye, 2006). 
However, over the last two decades several factors lead to the re-emergence of 
TB. On the one hand, the epidemic of the human immunodeficiency virus (HIV), 
mainly in Africa, and on the other hand the deterioration of the health care systems in 
Eastern Europe are two major factors leading to this re-emergence. The disease 
resurfaced to such an extent that the World Health Organization (WHO) declared it a 
global emergency in 1993. 
Today, an estimated one third of the world’s population is latently infected 
with TB (Harries and Dye, 2006). The WHO estimates that there have been 9.1 
million new infections and 1.5 million TB related deaths in 2006. Of these, 0.7 
million occurred in HIV positive individuals and 0.5 million were caused by drug 
resistant bacilli. As shown in Figure 1.1, most of the newly identified cases in 2006 
occurred in Africa and Asia (WHO, 2008a). 
Overall, the need for further discovery and development of TB drugs, vaccines 
and diagnostic tools is emphasized by the continued global burden of the disease, the 
increased occurrence of complicated cases and the fact that, even for the ‘short’ 
treatment regiment, a combination of drugs has to be taken for at least six months 
(Harries and Dye, 2006; Young et al., 2008). 
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Figure 1.1 Number of Estimated New Tuberculosis Cases in 2006. 
Based on estimates of the World Health Organization (WHO) there were 9.3 million new tuberculosis 
(TB) cases and 1.7 million TB related deaths in 2006. As shown by the global distribution, most of the 
new TB cases occurred in Asia and Africa (WHO, 2008a). 
 
1.1.2. Active and Latent Disease 
As a patient gets infected, the M. tuberculosis bacteria reach the lungs, 
multiply, escape to the local lymph node and eventually reach the rest of the body. In 
most cases, the immune response which follows infection results in cessation of 
bacterial growth without causing active disease (Harries and Dye, 2006). However, 
bacteria are usually not completely eliminated and remain in asymptomatic lesions 
where they can persist for a very long time under hypoxic conditions (Gomez and 
McKinney, 2004). For immunocompetent individuals who are latently TB infected, 
the lifetime risk of developing active TB is around 10%. In patients co-infected with 
HIV, this risk is increased to about 10% per year (Young et al., 2008). 
If active disease does develop, patients usually test positive for acid fast bacilli 
in a sputum smear, and they experience symptoms such as persistent cough and fever 
(Harries and Dye, 2006). Even if this primary infection is resolved by therapeutic 
treatment or through the action of the immune system, a small number of 
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mycobacteria can remain dormant in lesions for many years, after which re-activation 
or re-infection is possible (Gomez and McKinney, 2004). 
 
1.1.3. Eliciting Mostly a Cellular Immune Response 
As M. tuberculosis bacteria enter the lungs, they are engulfed by macrophages 
and subsequently a granuloma is formed. Most crucial for the immune response to TB 
are CD4+ T helper 1 (Th1) lymphocytes. CD4+ Th2 cells, CD8+ T cells and 
unconventional T cells are also present at the site of infection, but their role in the 
anti-TB response is less well understood (Kaufmann, 2003; Kaufmann and Parida, 
2008). Interestingly, unconventional CD1 restricted T cells have been shown to be 
activated by mycobacterial lipids (e.g. liporabinomannan and mycolic acids) 
(Kaufmann and Parida, 2008). 
All of the T cells in the granuloma produce interferon-γ (IFN-γ). This type 1 
cytokine activates macrophages, leading to a more effective killing of the invading 
bacteria. Th1 cells also produce additional cytokines, such as IL-2 and tumor necrosis 
factor α (TNF-α), which also play an important role in the anti-TB immune response 
(Kaufmann, 2003). 
 Overall, the host immune response to TB is highly skewed towards cellular 
immunity. Furthermore, the response of an individual will strongly contribute to the 
outcome of the host-pathogen interaction and determine whether or not active disease 
will develop. Thus, the immune response to TB has several unique characteristics, 
making it likely that disease specific immunological markers can be identified 
(Kaufmann and Parida, 2008). 
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1.1.4. Diagnosis 
Similarly to most of the currently available TB drugs, the most commonly 
used diagnostic tool for the disease, acid-fast sputum smear, was developed close to a 
century ago. It has been shown that 40-60% of patients with pulmonary TB go 
undiagnosed using this tool. An alternative to this microscopy based test is the 
culturing of mycobacteria from patients’ sputum. However, this requires six to eight 
weeks and technologies as well as expertise that are often not available in the most 
affected areas. Finally, the Mantoux test, also known as tuberculin skin test, is also 
commonly used, but does not provide conclusive evidence for active disease and 
additionally can be confounded by BCG vaccination. New diagnostic tools, 
potentially in the form of biomarkers, are therefore needed for reliable and fast 
diagnosis of TB patients, so that they can receive the necessary treatment leading to 
the containment of the disease (Garg et al., 2003; Young et al., 2008). 
Several effort have been made to develop novel diagnostic tools based on 
technologies such as enzyme-linked immuno sorbent assays (ELISA) or polymerase 
chain reaction (PCR) to detect antibodies against mycobacterial proteins or genetic 
material from the bacteria in human specimens, respectively (Garg et al., 2003). An 
example of these assays is the host immune system based IFN-γ release assay. T-cells 
of a TB infected individual are sensitized to M. tuberculosis proteins and upon 
challenge release IFN-γ. In the IFN-γ release assay, the cytokine release can be 
monitored colorimetrically and the number of sensitized T-cells determined (Lalvani, 
2007). Although these types of test have some potential, in a recently published 
evaluation of serum based rapid tests for TB, it was found that they do not perform 
particularly well (sensitivities from 1% to 60% and specificities from 53% to 99%) 
(WHO, 2008b). 
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1.2. TB Drug Discovery and Development 
1.2.1. Available Chemotherapy 
Most of the currently available first line TB drugs have been developed almost 
half a century ago and act on only a limited number of targets in the bacterial cells 
(see Figure 1.2). The drugs are effective in treating infections with drug sensitive 
strains, but given the very long treatment periods and issues with compliance, the 
drugs are considered insufficient to meat the current challenges. Therefore, novel 
drugs need to be developed. In particular for HIV co-infected patients, the current 
treatment options are insufficient and survival rates are low (Harries and Dye, 2006). 
Treatment options for drug resistant strains are available but show characteristic 
limitations of second line drugs with regard to toxicology, cost and increased duration 
of treatment (Harries and Dye, 2006; Young et al., 2008). 
 
 
Figure 1.2 Target of First Line TB Drugs. 
The targets for the four major first line TB drugs in M. tuberculosis are shown. The figure is curtsy of 
the National Institute of Allergy and Infectious Diseases (NIAID), USA. 
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 In addition to pharmacological drugs, the live attenuated Bacillus Calmette-
Guerin (BCG) vaccine is used to prevent TB. Although the vaccine has been shown to 
reduce the burden of severe childhood TB, it has only limited efficacy against adult 
forms of the disease and therefore further efforts are needed to develop a better TB 
vaccine (Harries and Dye, 2006; Young et al., 2008). 
 
1.2.2. Discovery of Novel Therapeutics 
In the early 1990’s, pharmaceutical companies largely abandoned anti-
microbial drug discovery. Only the availability of bacterial genomes and new 
possibilities of investigation sparked the interest in anti-microbial drug discovery 
again (Payne et al., 2007). 
Anti-microbial drug discovery has progressed to the use of highly reductionist 
tools such as high throughput screening (HTS), where a library of compounds is 
screened for activity against a genetically essential target, usually an enzyme (see 
Figure 1.3) (Rosamond and Allsop, 2000). It was hypothesized that compounds 
identified in these HTS would also show efficacy on cells and in the context of an 
infection in an organism (Drews, 2000; Young et al., 2008). 
However, this reductionist approach has major limitations and HTS does not 
necessarily result in useful leads (Payne et al., 2007). Even if leads are identified, 
translating the efficacy into cells or organisms remains difficult. For example, in vitro 
efficacy might not predict in vivo activity, since the behavior of the pathogen in the 
host may be vastly different from that in cultured conditions (personal communication 
Dr. Thomas Dick, NITD). 
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It is therefore believed by experts in the field that genetic validation of a target 
is insufficient to confirm its “vulnerability” on a cell and organism level. Hence 
compounds that show a potential, termed ‘tool compounds’, need to be validated in 
whole cell screens and even in animal models at an early stage in the lead 
optimization process, to focus medicinal chemistry efforts on compounds with true 
potential (see Figure 1.3) (Mukhopadhyay and Peterson, 2006; Payne et al., 2007). 
 
 
Figure 1.3 Drug Discovery Though Time. 
Throughout the history of drug discovery, the scale at which potential new compounds were tested has 
been continuously reduced, until efficacy of compounds was evaluated directly on a target protein in 
HTS (straight light gray arrows). This reductionist approach was believed to identify leads, which 
could later be modified by medicinal chemistry to translate the efficacy to target cells and even into the 
context of an organism (curved gray arrows). However, HTS have not resulted in the anticipated leads. 
Thus ‘tool compounds’ need to be screened on the target, in whole cells assays and in animals models 
(black arrows) early in the lead discovery process, prior to deciding if a compound should be 
developed into a drug (open arrow). 
 
 The discovery of novel TB drugs has been hampered by several 
M. tuberculosis specific factors such as the thick and very complex cell wall of the 
bacteria, their low metabolic activity during latency and the heterogeneity of the 
mycobacterial population that needs to be targeted. Further, anti-TB drug discovery 
has been restricted by limitations of the animal models available (see below) (Young 
et al., 2008). Lastly, clinical development of TB drugs has been constrained by 
financial issues arising from the fact that the endpoint of such studies is the relapse 
rate within two years after completing the treatment, requiring very large study 
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populations. Surrogate markers, which can predict treatment outcome, are needed to 
address these issues (Walzl et al., 2008). 
 Despite all of these challenges, there are several TB drugs in clinical 
evaluation and several compounds in pre-clinical testing (Lenaerts et al., 2008). 
 
1.2.3. Use of Animals in TB Drug Discovery 
With the lack of success of drug discovery relying only on genetic validation, 
easy-to-use and representative animal models are of vital importance and their 
improvement can facilitate the drug discovery process. Even though animal models of 
infections will never fully represent the disease in humans, they will likely mimic 
conditions in a human host better then in vitro culturing (Gomez and McKinney, 
2004). 
Various animal models for TB infection using numerous species (mice, 
rabbits, guinea-pigs and non-human primates) have been developed. Although there is 
a general consensus that TB infection in non-human primates best mimics human 
infection, work with these animals is very expensive and requires special facilities and 
knowhow. Work with rodents is a lot more common, and mice are used most often in 
TB animal research, especially to screen for new drugs. Mice have the advantage that 
their immunology is well understood and the necessary tools, such as antibodies, are 
readily available (Gomez and McKinney, 2004). However, issues such as the nature 
of the granuloma and the complexity of the read-out for drug efficacy studies in mice, 
remain an issue. 
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1.3. Lipidomics – Systems Scale Analysis of Lipids 
1.3.1. Lipids: Great Chemical and Functional Diversity 
1.3.1.1. Diverse Range of Molecular Species 
The term ‘lipid’ encompasses a broad range of chemical structures, which can 
be defined as being highly soluble in organic solvents. Even though this property of 
lipids is used to extract them from biological samples, some very polar ones, e.g. 
phosphoinositides or glycerolipids, would be excluded in this definition. A broader 
definition by Dr. William Christie (The Lipid Library) states that lipids are fatty acids 
along with their derivatives and substances which are biosynthetically or functionally 
related to these compounds (Wenk, 2006). Given their involvement in processes 
related to TB pathology two groups of lipids are of interest here: 
glycerophospholipids and shingolipids (see Discussion and Figure 1.4). 
Glycerophospholipids consist of a glycerol backbone to which two fatty acids 
are attached through ester linkages, at the stereospecific numbering (sn) position 1 
(sn-1) and 2 (sn-2). At the sn-3 position is a phosphate, which links the glycerol 
backbone to a head group. Based on the head group, a lipid get classified as a 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS) or 
phosphatidylcholine (PC), respectively (see Figure 1.4). Within these classes, the 
individual molecular species can have fatty acids (FA) with different length and 
saturation / unsaturation levels. Furthermore, in the case of PC and PE, the FA at the 
sn-1 position cannot only be esterified to the glycerol, but it can also be attached 
though an ether (e) or a venyl ether (p) linkage (Murphy, 2002). 
Sphingolipids on the other hand consist of a long chain sphingoid base, which 
can be linked to a FA through an amid bond to form a ceramide unit. The structure of 
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the attached FA again contributes to the diversity of the lipid class. Furthermore, 
similar to glycerophospholipids, different head groups can be attached to the 
ceramide. If a phosphocholine is attached, the resulting compound is referred to as 
sphingomyelin (SM) (see Figure 1.4) (Fahy et al., 2005; Murphy, 2002). 
 
 
Figure 1.4 Structures of Lipids Herein Studied. 
In the current study, two groups of lipids were of interest: glycerophospholipids (A1-4) and 
sphingolipids (B1-2). For both of these classes, an example of a backbone and the head groups of 
interest are shown. Glycerophospholipids are defined by the head groups (R1) forming 
phosphatidylcholines (A1), phosphatidylethanolamines (A2), phosphatidylserines (A3) or 
phosphatidylinositols (A4). Sphingolipid head groups (R2) define sphingomyelin (B1) or ceramide 
(B2). 
 
1.3.1.2. Range of Functions 
Given the large chemical diversity of lipids, it is not surprising that they have 
a very broad range of functions. Firstly, lipids, as caloric reservoirs, are used to store 
energy. Secondly, lipids form cellular membranes, which separate the inside of a cell 
from the environment and allow for the formation of organelles in eukaryotes. 
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Thirdly, lipids can also act as first and second messengers, and play a role in signal 
transduction and molecular recognition processes (van Meer et al., 2008). Uniquely a 
glycerophospholipid, which contains both hydrophilic and lipophilic parts, can result 
in a signal with two components, one of which (glycerol and FA) can signal through 
the membrane and the other (head group) is soluble and can diffuse into the cytosol 
(van Meer et al., 2008). Through these signaling functions, lipids have been 
implicated in the pathology of several diseases (Wymann and Schneiter, 2008). 
 
1.3.2. Lipidomics: Systems Scale Analysis of Lipids 
Over the last few years, “omics” disciplines (e.g. genomics, transcriptomics 
and proteomics) have attracted a lot of interest in biological research. These 
disciplines apply a “systems biology” approach. Such an approach simultaneously 
examines multiple components to understand the interaction of the individual parts 
and how they form an integrated whole. This is opposed to the traditionally used 
reductionist approach, where each component is evaluated individually, making it 
difficult to understand how properties of the entire system emerge (Sauer et al., 2007). 
The systems biology approach has been expanded to many other fields such as 
lipidomics, which is the systems scale analysis of lipids and their interacting partners 
in an organism (Taguchi et al., 2005; Wenk, 2005). 
In the past, lipidomics has lagged behind genomics and proteomics because of 
the lack of the necessary tools to profile lipids in complex mixtures. However, with 
the implementation of electrospray ionization (ESI) mass spectrometry (MS) and 
tandem MS, these technologies are now available and studies that compare the 
abundance of many lipids under different conditions have been conducted (Han and 
   13 
Gross, 2005; Wenk, 2005). Some technological limitations remain an issue in 
lipidomics. For instance, available MS methods are not able to measure the 
abundance of all lipids, especially detecting the very low abundant ones in a complex 
mixture remains difficult. From a practical point of view, it is important not to neglect 
the role of the lipid extraction and to emphasis the need to keep sample preparation 
very controlled and standardized (Wenk, 2005). 
In the area of bioinformatics and data analysis, lipidomics still lags behind 
other “omics” disciplines. For example, databases containing detailed functional, 
biological, physical and chemical information about a broad range of specific lipids 
are not yet available (Han and Gross, 2005; Wenk, 2005). Bioinformatics is 
additionally needed to adapt tools from the genomics and proteomics fields for the use 
in lipidomics. Furthermore, new and powerful tools have to be developed that can 
deal with the specific requirements of data resulting from large scale lipid studies 
(Wiest and Watkins, 2007). 
 
1.3.3. Lipid Biomarkers 
With the newly developed MS based approaches to measure the abundance of 
many lipids simultaneously using mass spectrometry (see below), lipidomics has been 
increasingly applied in biomarker studies. In such studies, dealing mostly but not 
exclusively with cancer, lipid profiles of patients are compared to those of controls 
and differences are identified. 
In two studies comparing plasma lipid profiles of ovarian and colorectal 
cancer patients to healthy controls respectively, lysophospholipids were found to be 
most indicative of the disease state. In particular, the authors of a study comparing 
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lysophospholipid profiles of ovarian cancer patients to healthy controls suggest that 
lysophosphatidic acid levels could potentially be used as diagnostic markers (Sutphen 
et al., 2004). When comparing the plasma phospholipid and sphingomyelin profiles of 
colorectal cancer patients to healthy controls, Zhao et al. found that the profiles differ 
mostly with respect to lysophospholipids. More thorough examination of the 
lysophospholipid profiles showed that plasma lysophosphatidylcholine (LPC) levels 
where altered in patients compared to controls. The authors suggest that therefore 
abundance of specific LCP in plasma may represent a useful biomarker for colorectal 
cancer (Zhao et al., 2007). A third example of a MS based lipidomics biomarker 
study, showed that LCP and phosphatidylethanolamine can potentially act as 
biomarkers for type 2 diabetes mellitus (Wang et al., 2005). 
 
1.4. Aim of Study 
Given the continued global burden of TB, there is a pressing need to develop 
novel drugs to treat the disease. However, TB drug discovery remains very difficult 
and novel compounds need to be validated on whole cells and even in animals early in 
the discovery process. In addition to culturing systems that mimic in vivo conditions 
closely, progress in the development and improvement of TB animal models needs to 
be made. A major disadvantage of the mouse TB model is that the only useful readout 
for drug efficacy studies is a method based colony forming units (CFU) in the murine 
lungs. A better readout, e.g. blood based biomarker, could facilitate the use of the TB 
mouse model. 
 The immune response following an active infection with M. tuberculosis has 
drastic affects on the host. The affect of this host response on the lipidome is 
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unknown, even though lipids have been shown to play a role in inflammatory 
response. 
 Here we use the mouse model of TB to study the effect of an infection on the 
murine lipidome. We hypothesize that blood lipid profiles of TB diseased mice will 
differ from those of non-diseased ones. 
1. We set out to identify host lipid biomarkers which differ between healthy and 
diseased mice and which “revert” to the healthy level upon TB treatment. 
2. We also aimed at developing machine learning tools that can differentiate 
between diseased and non-diseased mice based on their host lipid profiles. 
This kind of a tool could potentially provide a novel, non-lethal, blood based 
readout for pre-clinical drug efficacy studies in TB mouse models. It would be 
faster as compared to the counting of CFUs in the murine lungs and thereby, 
potentially simplify as well as speed up pre-clinical TB drug discovery. 




2. Materials and Methods 
 
 
   17 
2.1. Animal and BSL3 Work 
2.1.1. Mouse Experiment 
2.1.1.1. Intranasal Infection 
All animal work for this study was carried out by staff at the Novartis Institute 
for Tropical Disease (NITD) and approved by the International Animal Care and Use 
Committee (IUCAC) of NITD. Experiments were performed as part of a collaboration 
between our laboratory at National University of Singapore (NUS) and the unit of Dr. 
Veronique Dartois at NITD. Mice were obtained from the NUS Laboratory Animal 
Center. 
The workflow for the entire study is shown in Figure 2.1. 
On day zero, two groups of 30 BALB/c mice each were intranasially infected 
with 102 to 103 colony forming units (CFU) of Mycobacterium tuberculosis Beijing 
W4 (MTB). For the infection, animals were anesthetized and a drop (20 µL) of 
thawed MTB glycerol stock was placed at their nose for inhalation. One animal died 
during the infection procedure. A third group of 30 BALB/c mice was not infected 
and served as a healthy control group. For consistency, this control group was kept 
together with the infected animals in the biological safety level 3 (BSL-3) facility. 
 
2.1.1.2.  Drug Treatment 
Starting from one week post infection (p.i.) until sacrificing at five weeks p.i., 
one of the MTB infected groups was treated daily by gavage with a curative but far 
below LD50 dose of rifampicin (30mg drug / kg body weight) (Jayaram et al., 2003; 
Merck & Co., 1996). The remaining two groups were treated with vehicle, 0.25% 
carboxymethyl cellulose (CMC) sodium salt (Sigma) in water. During the course of 
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the experiment, four animals from the infected but untreated group needed to be 
sacrificed due to disease severity. 
 
 
Figure 2.1 Study Design to Identify Host Lipid Based Tuberculosis Biomarker. 
To identify host lipid biomarkers in mice infected with Mycobacterium tuberculosis Beijing W4, a 
study with three groups of mice was conducted. Two groups were infected, one of which was treated 
with a curative dose of rifampicin (Rif) and one only with vehicle (carboxymethyl cellulose, CMC) 
starting from one week post infection. Mice of the third group served as controls and were also vehicle 
treated. Four weeks after the beginning of the treatment, blood was collected from all animals, lipids 
extracted and analyzed using mass spectrometry. Obtained data were analyzed using statistical and 
machine learning approaches. 
 
2.1.1.3. Sample Collection 
After five weeks, all mice were terminally bled under anesthesia by retro-
orbital sinus puncture. Blood was collected into 2 mL screw cap tubes (Sarstedt) 
containing 10 µL of 0.5 M, pH 8 EDTA (Merck) and stored until further use at -80ºC. 
Five mock samples with EDTA and water instead of blood were also included. Lungs 
of all infected mice were collected, homogenized in 3 mL of PBS, processed for 
culturing according to standard protocols, plated and incubated for 3 weeks. Finally, 
bacterimia was assessed by counting colony forming units (CFU). Growth was only 
observed on the plates with lung homogenates of the infected, but not of the infected 
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and treated mice. Because of excessive growth, the number of colonies grown on 
eleven out of 26 plates could not be counted. 
We will refer to the three study groups as ‘healthy’ (uninfected and vehicle 
treated), ‘infected’ (TB infected and vehicle treated) and ‘cured’ (TB infected and 
rifampicine treated). For some of the analysis, animals were grouped as ‘diseased’ 
(infected only) and ‘non-diseased’ (healthy and cured). 
 
2.1.2. Sample Inactivation 
Dr. Anne K. Bendt of NUS kindly carried out the inactivation of the samples 
in the BSL-3 lab which was the initial step of the lipid extraction (see below). Briefly, 
94 µL of blood was transferred into a fresh 2 mL screw cap tube containing 500 µL of 
chloroform/methanol (2:1, v/v). Blood samples from four animals did not contain this 
amount of blood and were therefore excluded. Finally, samples were shaken over 
night at 4°C and transported to NUS the following day. 
 
2.2. Mass Spectrometry of Whole Blood Lipids 
2.2.1. Lipid Extraction 
Prior to continuing the lipid extraction, samples were re-labeled with a 
randomly assigned number and all subsequent steps were performed with the samples 
arranged according to this random numbering. 
The lipid extraction was carried out using a modified Bligh and Dyer method 
(Bligh and Dyer, 1959). After inactivation (above), the aqueous phase was separated 
from the lipid containing organic phase by adding 200 µL of ddH2O and 300 µL of 
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chloroform, vortexing for 30 seconds and centrifuging for 10 min at 20800 xg in an 
table top centrifuge (Eppendorf, 5417R). Subsequently, the lower organic phase was 
transferred into a 1.7 mL tube (Axygen, MCT-175-C) and the intermediate layer 
(“delipidated cells”) along with the aqueous phase were re-extracted as described 
above by adding 300 µL of fresh chloroform and shaking for 1 h at 4°C. Pooled 
organic extracts were dried in a SPD Speed Vac centrifuge (ThermoSavent) attached 
to a Universal Vacuum System (UVS400A, ThermoSavent) and the lipid films were 
stored at -80°C until further use. During the course of the lipid extraction, four 
samples were excluded because of pipetting errors. 
Overall, the study consisted of blood lipid extracts from 27 healthy, 21 
infected and 28 cured mice, resulting in a total of 76 samples. 
 
2.2.2. Mass Spectrometry 
2.2.2.1. Use of MS in Lipidomics 
Recently, mass spectrometry (MS) of lipids has greatly improved with the 
introduction of electron spray ionization (ESI) (Griffiths et al., 2001; Han and Gross, 
2005; Pulfer and Murphy, 2003). For this ‘soft’ ionization, the solution containing the 
compounds of interest is forced through a narrow orifice, leading to the formation of a 
spray of small droplets that enter the ionization chamber (Fenn et al., 1989; Han and 
Gross, 2005). By applying an electronic potential between the orifice and the mass 
analyzer, the formed droplets, if ionizable, become charged (e.g. droplets become 
positively charged in the positive ion-mode) and are directed towards the mass 
analyzer. The degree to which a given compound can be ionized is based on its 
physical and chemical properties. As the charged droplets move, they are desolvated, 
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eventually resulting in the separation of individual ions which enter the mass analyzer 
(Han and Gross, 2005). 
When performing MS in single stage mode, all ions within a specified range 
of mass to charge (m/z) ratios pass through the mass analyzer. However, with the use 
of tandem MS (MS/MS) and a quadrupole time of flight (Q-TOF) instrument, specific 
ions can be selected (Aebersold and Mann, 2003). Employing collision-induced 
dissociation (CID), it is possible to perform product ion scans (see below), precursor 
ion scans, neutral loss scans, or multiple reaction monitoring (MRM, also called 
selected reaction monitoring, see below) (de Hoffmann, 1996; Griffiths et al., 2001). 
Schematic representations of these different analytical approaches are shown in 
Figure 2.2. 
2.2.2.2. Biased Analysis by Multiple Reaction Monitoring (MRM) 
Here, an MRM based approach was used to measure the abundance of specific 
ions in mouse blood lipid extracts (see Figure 2.2). This method is considered biased 
or targeted, because only the intensities of specified and known ions are measured. 
For each ion of interest, two m/z ratios, a so called transition, had to be specified. The 
first m/z ratio defines the parent ion and the second one the daughter ions formed 
during CID. For the analysis of lipids, the second mass analyzer was set to an m/z 
ratio corresponding to a specific lipid head group or to an m/z ratio that corresponded 
to a parent ion that has lost a lipid head group. For the current study it was set at 
m/z 196.1 for phosphatidylethanolamine (PE), m/z 241.1 for phosphatidylinositol 
(PI), m/z 184.1 for phosphatidylcholine (PC), m/z 264.4 for ceramide and m/z 184.1 
for sphingomyeline (SM). To measure the abundance of phosphatidylserine (PS) it 
was set at an m/z ratio that is 87 less than that specified in the first mass analyzer 
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(neutral loss m/z 87) (Taguchi et al., 2005). The first mass analyzer was set to define 
the total mass of the ion of interest. It therefore specified the total number of carbon 
atoms and double bonds in the fatty acids chains of a given lipid. Theoretical 
transitions for a lipid of a given class and with a specific number of carbon atoms and 
double bonds in the fatty acid can be computed (Murphy, 2002). However, to 
determine the exact combination of FA of a lipid, product ion scans needed to be 
performed (see below). 
 
 
Figure 2.2 Analytical Approaches in MS/MS. 
Product ion scan (A), precursor ion scan (B), neutral loss scan (C) and multiple reaction monitoring 
(D), with their respective settings for the two mass analyzers (MS1 and MS2). In the collision cell, ions 
that pass through the first mass analyzer (MS1) undergo collision-induced dissociation (CID) and the 
product ions enter the second mass analyzer. Ions that pass through this third chamber (MS2) reach the 
detector, where their intensity is recorded. For neutral loss scans, only ions for which the m/z ratio is 
“a” less then that of the ion passing through MS1 are selected in MS2. Adopted from de Hoffmann and 
Griffiths and co-workers (de Hoffmann, 1996; Griffiths et al., 2001). 
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In this study, PE, PI and PS were measured in the negative ion mode and PC, 
ceramide and SM were acquired in the positive ion mode. 
For the systems scale analysis of lipids a total of 160 transitions were 
measured using an ABI 4000QT (Applied Biosystems) quadruple time of flight 
instrument in MRM mode. Table 2.1 lists the number of lipids of each class included 
here. The transitions used here have been previously established by members of the 
MRW lab in liquid chromatography (LC) MS and MS/MS studies. 
For MS, lipid extracts were resuspended in 500 µL of chloroform/methanol 
(1:1, vol/vol) and 30 µL were injected using an autosampler (1100 Series, Agilent 
Technologies) for measurements in either of the ESI modes. MS settings for both 
positive and negative ESI modes have been previously established by other members 
of the lab and are shown in Table 2.2. Run time for the two modes were set at 
1.5 minutes for the positive and 2 minutes for the negative mode respectively. 
Table 2.1 Number of Lipids in each Class Studied. 
Lipid Class Lyso Form Phospholipid Form 
PE 8 40 
PI 6 22 
PS 4 9 






Table 2.2 Settings of MS in MRM Mode. 
 negative mode positive mode 
dwelling time (ms) 15 15 
declustering potential (V) 90 -80 to -140 
entrance potential (V) 10 -10 
collision energy (V) 45 to 65 -22 to -60 
collision cell exit potential (V) 5 to 14 -10 
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2.2.2.3. Molecular Species Characterization by MS/MS 
To perform fragment ion scans (MS/MS) to confirm the identity of the lipids 
of interest, a QTOF instrument (Q-TOF micro, Waters) was used. To attain the 
required signal intensity for MS/MS, all samples were pooled and concentrated using 
a vacuum centrifuge as described above. For analysis samples were injected by a 
syringe pump and MS/MS was performed by scanning for fragment ions in a range of 
80m/z to about 50m/z above the m/z of the parent ion. For the individual lipid classes, 
collision energies were manipulated as given in Table 2.3, to obtain spectra 
containing fragment ions. MS/MS was employed in the same modes as the MRM 
analysis for the respective lipid classes. Since FA do not ionize in positive mode, the 
corresponding ions could only be used to confirmed to presence of the expected head 
group. 
Table 2.3 Collision Energies for MS/MS 
Lipid Class Range of Collision Energy (V) Ionization Mode 
PS 25-35 negative 
PE 35-45 negative 
PI 40-50 negative 
PC 40-70 positive 
 
2.3. Data Analysis 
2.3.1. Raw Data Analysis 
2.3.1.1. Statistical Terminology 
For the purpose of this thesis, the following terminology is used: the measured 
variables (MRM transitions) will be referred to as ‘features’. The term ‘group’ refers 
to any of the three groups of mice, which are healthy, infected and cured. An 
individual lipid intensity measured in one ‘sample’ (lipid extract from blood of one 
mouse from any of the groups) will be termed ‘observation’. 
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2.3.1.2. Identifying Unreliable Transitions 
Mass spectrometry data were extracted from the Analyst software (version 
1.4.2, Applied Biosystems) using a MatLab (version R2006a, MathWorks) tool 
previously developed in our lab. For all samples, raw intensities between 0 to 90 
seconds of features measured in the negative ESI mode and between 0 to 120 seconds 
for those measured in the positive ESI mode were exported as text files. 
To identify features with high counts in mock extracted samples (n=5), the 
average feature intensities were calculated and plotted. Prior to further analysis, 
features with mock counts much higher than all others were visually identified and 
excluded from the data set. 
Based on previous studies (personal communication Dr. Anne K. Bendt, 
NUS), it is known that there is some level of background noise when measuring 
MRM transitions in both the negative and positive ion modes. To ensure that all data 
considered for further analysis was above background noise, average intensities for 
each feature across all blood lipid extracts were plotted. A noise threshold of an 
intensity of 200 in the positive and 50 in the negative mode was applied. All features 
having average intensity below the respective threshold were excluded from the data 
set. 
 
2.3.1.3. Identifying Outliers and Assessing Normality 
To identify outliers, standard scores (Z-scores), which are defined as the 
number of standard deviations (SD) a particular observations deviates from the mean, 
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were calculated. Within-group Z-scores were calculated for each feature. Z-scores 
above 3 were deemed outliers and their distribution over the complete data set was 
visualized in a heat map. To evaluate if the observed number of outliers was more 
than what would be expected in a normal distribution, the expected number of 
observations that have Z-scores above 3 or 3.5 were estimated, using the pnorm() 
function in R (version 2.7.1, http://www.r-project.org/). 
In this study, the number of observations with Z-scores above 3 SD was 
higher than expected (see Results). Conventionally, outliers are removed and replaced 
by missing values. However, here removal of data points was not an option, since 
missing values would affect outcome of the normalization (see below). Based on this, 
a second data set was created, with each outlier replaced by within-group mean of the 
remaining observations for that feature. Both data sets were used for all subsequent 
analysis. 
To gain further insight into the raw data, the normality of the distribution of 
the observations was assessed. For this, a code was written in R to compute p-values 
of the Shapiro-Wilk test for each feature within the three groups (see 6.1.1). The 
Shapiro-Wilk test was used since it is widely considered to be one of the most reliable 
tests for non-normality, especially for small to medium sample sizes (Royston, 1995; 
Shapiro and Wilk, 1965). The null hypothesis of the test is rejected in case of small p-
values, suggesting that samples are likely not from a normal distribution. Resulting p-
values for each of the groups and across all features were visualized using a heat map. 
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2.3.2. Normalizing Data 
MRM derived data were normalized to account for between sample variation, 
which could for example be due to unequal amounts of starting material. Different 
approaches can be used to normalize MS data. In this study, data was normalized to 
total ion counts of the respective sample (Wiest and Watkins, 2007). Therefore, 
normalized intensities represent the fraction of the overall signal of a sample given by 
one feature. Measurements from the two ESI modes (positive and negative) were 
normalized individually. Normalized intensities were multiplied by one thousand in 
order to not encounter rounding errors during subsequent analysis. 
To assess between- and within-group variation, normalized data was plotted in 
a heat map. 
 
2.3.3. Identifying Potential Biomarker Lipids 
2.3.3.1. Comparing Means of Three Groups 
For each feature, we determined if the means of the three groups were 
statistically different by using analysis of variance (ANOVA) and Kruskal-Wallis test 
in SPSS (version 17.0, SPSS Inc.). ANOVA, the parametric test to compare two or 
more means, assumes equal variance and that the observations come from a normal 
distribution (Zar, 1999). To assess normality, the Shapiro-Wilk test (see above) was 
applied to each of the features in each group separately. To test for the assumption of 
equal variance, i.e. homogeneity of variance, the Levene’s test was used. Compared to 
other tests for homogeneity, the Levene’s test has the advantage of being less 
sensitive to departures from normality (Olkin, 1960). The null hypothesis is rejected 
in case of small p-values, suggesting that the groups have unequal variances. 
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Calculated p-values, which were used to evaluate the assumptions of the ANOVA, 
were represented in heat maps. 
Large numbers of statistical hypothesis testing exacerbate the issue of false 
discovery rate. For instance, for a significance level of 0.05, one in twenty tests will 
result in a statistically significant result by chance. We used Bonferroni correction to 
deal with such issues, whereby a chosen significance level is divided by the number 
of statistical tests performed. Hence, the more tests performed, the greater the 
decrease of the p-value cutoff at which a test result is deemed significant. However, it 
is important to note that the result will be significant at the chosen p-value rather the 
at the Bonferroni corrected p-value (Bland and Altman, 1995). Results from the 
Shapiro-Wilk and Levene’s test were both also interpreted using Bonferroni corrected 
p-values and the results shown in the heat map. 
Although ANOVA is a parametric test, it is considered robust with respect to 
even considerable deviations from the assumptions made (Zar, 1999). Furthermore, 
ANOVA allows for post hoc tests (see below), which are not available for non-
parametric tests (Zar, 1999). It was therefore decided to apply this test to all features, 
since none of them were found to be very strongly skewed or to greatly violate the 
assumption of equal variance. Furthermore, differences between means were 
evaluated using the Kruskal Wallis test, which is the non-parametric equivalent of 
ANOVA. Calculated p-values were adjusted using Bonferroni correction and the 
corrected as well as the original p-values represented in heat maps. 
For all features which differ significantly between the three groups, a Tukey’s 
Honestly Significant Difference (HSD) test was performed. This multiple comparison 
identifies homogeneous subsets, which places experimental groups into the same 
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subset if their observations appear to be from the same population. The Tukey’s HSD 
test makes the same assumptions as ANOVA and is also considered robust to 
departures from normality (Zar, 1999). 
 
2.3.3.2. Homogeneous Subsets: “Reverting” Lipids 
Means of features which did not show a statistically significant difference 
between the cured and the healthy groups, but at the same time were different 
compared to the infected group, were identified using Tukey’s HSD homogeneous 
subsets. Features reverting back to the healthy state in cured animals were deemed of 
particular interest, because they appear to reflect the disease state and respond to the 
treatment. Subsets were selected considering a significant difference between 
diseased and non-diseased (p-value <0.01) but a non-significant difference between 
healthy and cured (p-value >0.01). Furthermore, we ranked the degree of significance 
/ non-significance between the three groups, to rank the homogeneous subsets. The p-
values calculated for comparison of the three groups (healthy, infected, cured) were 
grouped (healthy vs infected or cured vs infected: <0.01, <0.001, <0.0001 or <0.0001; 
and for healthy vs cured >0.1, >0.05, >0.01, or <0.01). Further identification of 
features showing the reverting trend was performed using scatter plots, which show 
the full distribution of the data, and error plots, which show the mean +/- 2 standard 
error (SE).  
 
   30 
2.3.4. Building a Diagnostic Model 
2.3.4.1. Statistical Differences Between Diseased and Non-Diseased 
Additionally, we aimed at building a machine learning tool that could 
differentiate between non-diseased and diseased animals. For this samples from cured 
and healthy animals were grouped together (‘non-diseased’) and compared to infected 
animals (‘diseased’). Student’s t-test was used to assess differences between diseased 
and non-diseased animals with regard to the 139 features measured. Given the non-
normal distribution of some features, differences were also assessed using the non-
parametric Mann Whitney U test (also known as Wilcoxon rank-sum test) (Zar, 
1999). Resulting p-values were grouped, corrected by the Bonferroni method and 
presented in heat maps. 
 
2.3.4.2. Recursive – Support Vector Machines 
2.3.4.2.1. Use of Support Vector Machines in Data Mining 
With the availability of large ‘omics’ data set, the interest in building 
diagnostic tools that can, for example, determine if a patients has a disease, has 
greatly increased over the last few years (Bellazzi and Zupan, 2008). So far, newly 
developed methods have mainly been applied to microarray data in attempts to 
diagnose cancer. 
Several issues are of great importance when applying any machine learning 
tool. Especially data sets with many more features than samples are prone to cause 
‘over-fitting’, meaning that the created model is very specific to the training data set 
but does not perform well on others. One measure that needs to be taken to prevent 
over-fitting is feature reduction, i.e. decreasing the number of features to be below or 
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around the number of samples used. Assessing models based on their accuracy in 
cross validation (CV) (see below) is a powerful method to overcome data over-fitting 
and needs to be performed. For CV, the available data is split into a test and a training 
set, whereby the training set is used to build a model and the test set subsequently 
used to test the model (Huang et al., 2006; Huang and Kecman, 2005). 
Of the different data mining tools, support vector machines (SVM) are 
considered very powerful in terms of predictive accuracy. They have been shown to 
perform well in many areas of biological analysis (Bellazzi and Zupan, 2008; Huang 
and Kecman, 2005). Briefly, SVM compute a hyperplane between the samples of two 
different groups in a multidimensional space, maximizing the distance between 
samples on either side. Samples closest to this hyperplane are referred to as support 
vectors (see Figure 2.3). For real data sets, an optimal hyperplane may not exist, and 
thus the ‘soft margin’ method needs to be applied, where a hyperplane is drawn to 
best separate the two groups and some samples are allowed to be on the “wrong” side. 
When computing the equations of the hyperplane, different functions, termed kernels, 
can be used. Based on previous experience of our lab, linear kernels were chosen.  
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Figure 2.3 Schematic Depiction of Hyperplane Computed by Support Vector Machines (SVM). 
SVM computes an (optimal) hyperplane that separates samples from two different groups (here shown 
as X and O). Support vectors on either side of the hyperplane define the maximum margin hyperplanes. 
Adopted from Bellazzi and Zupan (Bellazzi and Zupan, 2008). 
 
2.3.4.2.2. SVM Parameter Optimization 
Cost (C) is the only parameter for linear SVM which is of importance. When 
finding the hyperplane which separates the two groups from each other, the cost 
parameter controls the softness of the margins. If C is set larger, the margins become 
harder and no data points are allowed to be within them. The R package (e1071) used 
here to build SVM has a function, tune.svm(), which can be used to optimize the 
cost parameter (see Step 5 in 6.1.2). As shown by Huang and Kecman, optimizing C 
can both reduce over-fitting and improve feature selection (Huang and Kecman, 
2005). 
Here the cost parameter was optimized over a range of 2x10-6 to 2x106 in log10 
intervals, using the R code given in 6.1.2 (Step 5). The optimized cost parameter was 
then used to run the SVM function (see below). 
 
2.3.4.2.3. Feature Reduction by R-SVM 
With the increased application of SVM for analysis of biological data, 
approaches for feature selection / reduction have been developed (Guyon et al., 2002). 
However, the SVM recursive feature elimination (SVM-RFE) method developed by 
Guyon et al. was later found to have several flaws (Huang and Kecman, 2005; Zhang 
et al., 2006). Most importantly, this initially developed approach does not carry out 
true CV when it performs the feature reduction. For SVM-RFE, the data is split into 
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training and test set at each iteration. Performing CV more stringently and splitting 
the data into training and test only once can overcome this problem. An R code for 
this approach, termed recursive SVM (R-SVM), has been developed by Zhang et al. 
and was slightly modified by us for the present study (Zhang et al., 2006). Feature 
reduction in R-SVM was performed by assessing the contribution of each feature to a 
model by two criteria: (1) the mean difference, i.e. the difference in the means, of a 
given feature and (2) a coefficient that represents the weight of each feature’s 
contribution to defining the hyperplane (Zhang et al., 2006). 
Two additional outputs were introduced into the code. The first one captures 
the error that is made in predicting the training data set, which will help to monitor 
over-fitting. The second output captures the prediction result of the cross validation to 
compute sensitivity and specificity. Furthermore, the initial steps of the script were 
separated out into individual commands (see 6.1.2). With the code and instructions 
given in 6.1.2, feature reduction using SVM can be performed to produce the 
following outputs. For each stage of feature reduction, the function computes the CV 
error, the self-prediction error (error when predicting the training data), the confusion 
matrix and the list of features, which had been selected at each stage of feature 
reduction. 
Here SVM were trained to differentiate between diseased and non-diseased 
mice, based on the blood lipid profile of the animals. For this purpose, healthy and 
cured animals were merged to form the group termed ‘non-diseased’. SVM were 
trained to classify between diseased and non-diseased animals. We used a leave-one-
out CV approach, whereby one sample is removed from the data set and the 
remaining samples are used to train the SVM. This process is repeated until every 
sample was used once to test the trained model (Ambroise and McLachlan, 2002). For 
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feature reduction, a first model was built using all the measured features and 
subsequently features were reduced finally leading to a model using only two features 
to differentiate between diseased and non-diseased animals. Based on the CV 
prediction errors during this feature reduction process the best model could be 
selected. 
As for the results of the R-SVM, the percent error in test set and training set 
prediction were plotted over the steps of the feature reduction. Features used for the 
best performing model were identified and the number of true positive, true negative, 
false positive and false negative predictions for that model were captured to calculate 
sensitivity and specificity. 
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3.1. Rifampicin can clear M. tuberculosis Beijing W4 infection in 
mice 
To assess the effect of M. tuberculosis Beijing W4 (MTB) infection on the lipid 
profiles of mice, an experiment with three groups of animals was conducted. Two of 
the groups were infected with MTB and one of them treated with a curative dose of 
rifampicin (Jayaram et al., 2003). Animals in the third group were maintained as 
healthy control mice and not infected. To confirm that the rifampicin dose used was 
sufficient to clear the infection in the treated group, lungs of all the infected animals 
(n=26) were collected at the end of the study and bacterimia assessed by counting 
CFU (see Materials and Methods). Dilutions for some of the samples were 
insufficient, hence single colonies could not to be counted. CFU counts of all other 
samples (n=15) are shown in Figure 3.1. After four weeks of treatment with 
rifampicin, the lungs of MTB infected mice were free of CFU. This confirms that the 
mice infected with M. tuberculosis Beijing W4 can be cured, in terms of CFU, using 
30mg/kg rifampicin and is in agreement with previously reported findings of Jayaram 
et al. (Jayaram et al., 2003). 
 
 
Figure 3.1 Colony Forming Units (CFU) in MTB Infected and Treated Mice. 
Bacterimea of M. tuberculosis Beijing W4 (MTB) infected mice was assessed using CFU counts. After 
four weeks of rifampicin treatment (30mg/kg) of some of the mice, lungs from both untreated and 
treated mice were collected, homogenized, diluted and plated. No CFU were observed in the treated 
mice. 
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3.2. Lipid profiles vary between TB infected, cured and healthy 
mice 
3.2.1. Analyzing Raw Data Identifies Unreliable Features and 
Observations 
At the end of the experiment, blood was collected from all animals and lipids 
were extracted (see Materials and Methods). Using mass spectrometry, the intensities 
of 160 MRM transitions (‘features’) were measured in all blood-lipid extracts (n=77) 
as well as mock samples (n=5). Initially, raw MS data were analyzed to identify 
features that were high in the mock extractions and those that were within background 
noise in all samples. 
Examining mock counts and plotting their average across all features revealed 
that 14 features had high counts in the mock samples (see Figure 3.2 and data not 
shown). These features were thus considered being unreliable and were removed prior 
to further data analysis (see Table 3.1). 
Plotting the average intensity of each feature across all blood-lipid extracts 
revealed that the signal for seven features was consistently below the previously 
established noise levels (see Materials and Methods, Figure 3.1 and data not shown). 
All of these features were from the ones measured in the positive ion mode. They 
were also removed before further data analysis (see Table 3.1). 
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Figure 3.2 Raw Data Analysis: High Mock Counts and Low Lipid-Extract Counts. 
Lipids were extracted from blood of healthy, TB infected and TB infected but cured mice and analyzed 
by mass spectrometry. Overall 160 MRM transitions were measured for each sample. Raw data were 
analyzed by plotting average intensities of the mock (n=5) (A) and blood-lipid extracts (n=77) (B). 
Overall, 21 transitions were found to be unreliable based on this raw data analysis and removed from 
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Table 3.1 Transitions Removed Based on Raw Data Analysis 
Mode Transitions Removed because 
Neg. 571.3/241.1 high mock counts 
Neg. 597.4/241.1 high mock counts 
Neg. 599.4/241.1 high mock counts 
Neg. 833.7/241.1 high mock counts 
Pos. 482.6/184.1 below background signal 
Pos. 522.6/184.1 high mock counts 
Pos. 715.9/184.1 high mock counts 
Pos. 722.9/184.1 below background signal 
Pos. 742.9/184.1 below background signal 
Pos. 768.9/184.1 high mock counts 
Pos. 772.9/184.1 high mock counts 
Pos. 782.9/184.1 high mock counts 
Pos. 846/184.1 high mock counts 
Pos. 848/184.1 high mock counts 
Pos. 538.7/264.4 below background signal 
Pos. 566.7/264.4 high mock counts 
Pos. 594.7/264.4 high mock counts 
Pos. 622.7/264.4 below background signal 
Pos. 648.8/264.4 below background signal 
Pos. 650.8/264.4 below background signal 
Pos. 652.8/264.4 high mock counts 
 
3.2.2. Several Observations May be Outliers 
To identify outliers, Z-scores were calculated within each group and for each 
feature. Overall 46 observations in eleven samples were found to deviate by more 
than 3 SD from the respective mean, six of these deviated by more than 3.5 SD. The 
distribution of these outliers as well as the degree to which they deviate from the 
respective means is shown in Figure 3.3. Because the number of observations that 
have Z-scores of more than three was higher than expected, a second data set with 
these observations replaced by the respective mean was created. Re-calculating Z-
scores in the second data set showed that six observations with Z-scores of above 3 
and zero with Z-scores of more than 3.5 remained (data not shown). This number of 
outliers in the second data set is less than what is expected and acceptable. The data 
set with the outliers replaced will show how these extreme measurements may affect 
the outcome of the study. 




Figure 3.3 Heat Map of Outliers. 
To identify outliers in the raw MS data, Z-scores were calculated for each feature with respect to the 
corresponding within-group mean. The distribution of the outliers with Z-scores between 3 and 3.5 
(gray) or above 3.5 (black) is shown in a heat map. Individual animals are in the columns and features 
measured in the rows. For each sample 160 features were measured. Abbreviations: PE: 
phosphatidylethanolamine, PI: phosphatidylinositol, PS: phosphatidylserine, PC: phosphatidylcholine, 
and SM: sphingomyelin. 
 
3.2.3. Observations for Some Features Distributed Non-Normally 
To gain an understanding of the normality of our data set, the within group 
distribution for each feature was evaluated by performing a Shapiro-Wilk normality 
test. As shown in Figure 3.4, most observations distributed normally according to the 
Shapiro-Wilk test. However, some features in all three groups (55/417=13% in the 
data with all observations and 39/417=9.4% in the one with outliers replaced) 
distributed non-normally according to a Shapiro-Wilk test (p-value < 0.001). 
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Figure 3.4 Evaluating Normality of Raw Data. 
Raw MS data were evaluated for normality using the Shapiro-Wilk test. The p-values of the test are 
shown in the heat maps with different shades of gray representing different degrees of significance and 
black being the most significant (see scale). For the Shapiro-Wilk test, a smaller p-value indicates that 
observations are not from a normal distribution. The test was computed for each feature (rows) and 
each of the groups (columns) separately. Test results for the data set with all observations (left) and the 
one with outliers replaced (right) are shown. 
 
 Following this raw data analysis, the measurements were normalized to total 
ion counts. In this normalization it is assumed that the overall amount of the measured 
ions is constant in all samples and that only the relative abundances of individual 
species varies. 
 
3.2.4. Statistically Significant Differences Exist Between All Groups 
To visually inspect the overall variation in the normalized data between 
samples as well as between the three different groups, all of the data was plotted in a 
heat map (see Figure 3.5). Between group variation could be observed for example for 
the PS, which appeared to be relatively less abundant in the healthy and cured as 
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compared to the infected animals. Differences between individual animals (samples) 
could be seen where individual columns differ from the ones to the right or left. 
 
Figure 3.5 Heat Map of All Normalized Data. 
An animal experiment with three groups (healthy, infected, cured) was designed to investigate the 
effect of MTB infection on the host lipid profiles of mice. Lipids (PE, PI, PS, PC and SM) were 
measured by MS using an MRM approach. In the raw data several observations were identified as 
outliers and a second data set, was created with the outliers being replaced by the respective means 
(outliers removed). Further, raw data analysis led to the removal of unreliable measurements. Finally, 
measured intensities for 139 transitions were normalized to total ion count for each sample. The 
normalized data is shown in a heat map with darker areas representing the relatively more abundant 
ions. The left panel shows normalized data for the data set with all observations and the right one that 
with the outliers replaced. 
 
To identify features for which there were statistical differences between the 
three groups, ANOVA as well as Kruskal-Wallis tests were performed. To test for the 
two assumptions of ANOVA, the Levene’s Test, across all three groups, and the 
Shapiro-Wilk test, within each group, were performed respectively. 
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Computed p-values from these tests are shown in Figure 3.6. For the Levene’s 
Test, p-values were grouped as either < 0.05 or < 0.005. Furthermore, results were 
Bonferroni corrected to a p-value of 0.05. As shown in Figure 3.6, variances for 
several features were found to be significantly different (p-value < 0.05). This was the 
case for both, the data set containing all observations and the one with outliers 
replaced. Only a small number of features, three in the data set with all observations, 
and four in the one with outliers replaced, were found to be significant at a p-
value < 0.005. No observations were significant at a Bonferroni corrected p-
value < 0.05. As further shown in Figure 3.6, the outcomes of the Levene’s Test were 
similar between the data set with all the observations and the one with the outliers 
replaced. However, a few features were found to violate the assumption of equal 
variance only in one of the two data sets. Also, the features that violated the 
assumption of equal variance, to any extend, were fairly equally distributed between 
the two modes of measurement (PE, PI and PS versus PC and SM). 
The Shapiro-Wilk test was performed for each of the three groups separately, 
and results were grouped in the same way as for the Levene’s test. As shown in 
Figure 3.6, several features, especially in the infected group of the data set with all 
observations, were found to violate the assumption of normality with Bonferroni 
corrected p-values < 0.05. In particularly, the data set containing all observations 
appeared to have more features which distributed non-normally in positive mode (PC 
and SM) than in negative mode. 
ANOVA was applied to all features, even in cases were some assumptions 
were violated. This is supported by the fact that ANOVA is a robust to violations of 
normality (see Materials and Methods, Figure 3.6). Resulting p-values of ANOVA 
and Kruskal-Wallis test were corrected by the Bonferroni method (p-values <0.01) 
   44 
and the original as well as the corrected values grouped (<0.01, <0.001, <0.0001) for 
visualization. 
ANOVA and Kruskal-Wallis test performed on the data set containing all 
observations were generally consistent, although ANOVA gave more statistically 
significant results for some features. As for the significant level at Bonferroni 
corrected p-values <0.01, the two tests were mostly (81%) consistent. There were two 
and four features that were found to be statistically significant (Bonferroni corrected 
p-value <0.01) using either exclusively the Kuskal-Wallis test or ANOVA 
respectively. 
On the other hand, when using the data set with the outliers replaced, we 
obtained consistent results for 70% (21/30) of the features at a Bonferroni corrected p-
value cutoff of <0.01. As for the disagreements, three and six features were only 
significantly different using either exclusively the Kruskal-Wallis test or using 
ANOVA, respectively. 
In most cases, the significant differences observed by ANOVA and Kruskal-
Wallis test were detected in both data sets. The ANOVA was unaffected by replacing 
outliers 22 out of 26 times (85%) and for the Kruskal-Wallis test, this was the case for 
23 out of 28 times (82%). However, three of the ANOVA identified features that were 
not significant for both of the data sets were only significant when considering all 
observations, and only one when considering the data set with the outliers replaced. 
Of the five features that were statistically significant using the Kruskal-Wallis test in 
only one of the two data sets, four were only significant in the data set considering all 
observations and only one using the data set with the outliers removed. Finally, outlier 
replacement did not affect the significance level at a Bonferroni corrected p-value of 
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<0.01 for any of the transitions for which the two tests agreed, meaning that if both of 
the tests found a feature to vary to this degree of significance, replacing outlier did not 
affect this result. 
 
 
Figure 3.6 Significant Differences Between Host Lipid Profiles of TB Infected Animals. 
To compare normalized abundances of 139 lipids between healthy, TB infected and cured mice 
Kruskal-Wallis test (K-W test) and analysis of variance (ANOVA) were performed. To test for the 
assumptions of ANOVA, the Shapiro-Wilk test (S-W test) was used to assess the normality of the 
distribution in each of the three groups and the Levene’s Test was used to assess homogeneity between 
the groups. Results in terms of p-values of these two tests, i.e. features that distribute non-normally or 
features for which variances cannot be assumed equal, are shown. Light gray represents significance at 
a p-value of <0.05, dark gray at <0.005 and black at a Bonferroni corrected p-value of <0.05. 
Outcomes of the K-W test and ANOVA are coded: light gray for significance at p-value <0.01, dark 
gray <0.001 and black <0.0001. Furthermore, the last column for these two tests shows significance at 
a Bonfferoni corrected (B cor.) p-value of <0.01. Finally interpretation of the results from the Tukey 
post hoc test identified homogeneous subsets (Hom. Subset) of interest. These are again colored with 
darker color representing the features which follow the trend of interest more closely. 
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3.3. Levels of Potential Biomarker Lipids “Revert” to Healthy 
State Upon Drug Treatment 
For the features with statistical differences between means, a post hoc Tukey’s 
test was done to determine between which of the three groups the statistical 
differences exist. Features that might be indicative of TB infection were chosen 
according to a specific pattern of statistical differences between the three groups. 
Features for which the relative abundance was statistically different between diseased 
and non-diseased (healthy and cured) but showed no difference between cured and 
healthy here identified as “reverting” lipids. The level of significance between 
diseased and the two non-diseased groups as well as the level of non-significance 
between healthy and cured were considered when assessing the degree to which any 
features followed the reverting phenotype. Features of interest and the degree to 
which they follow the trend of interest are depicted in Figure 3.6. The degree to which 
a feature is of interest with respect to these criteria is the same in both data sets. In 
addition to these features that were identified using both data sets, one feature was 
identified only in either one of them. In the data set with all observations, this feature 
exerted the reverting phenotype to intermediate degree and was a PE (38:4p or 35:5e, 
750.6/196.1). In the data set with the outliers replaced, the uniquely identified 
reverting feature was a SM (18/16:1, 703.9/184.1) showing the trend to a low degree. 
For both data sets, five features were identified as showing a strongly reverting 
phenotype. 
To further investigate the features showing the reverting phenotype, scatter and 
error plots were drawn (see Figure 3.6). Of the 20 features that were found to be of 
interest across both data sets, the visual inspection revealed seven features, which do 
not appear to show the desired trend very clearly. Of these features five were 
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identified in both data sets and the other two were the ones only identified in one of 
the two data sets. These features did not pass visual inspection for the between group 
trend of interest, because the outcome appeared either to be strongly influenced by 
extreme observations or the observations within one group were spread over a wide 
range. Representative examples of such cases are shown in Figure 3.7. Additionally, 
this figures show an example of a feature (PC 38:3p or 38:4e) where the desired trend 
was confirmed through visual inspection. All of the graphs shown in Figure 3.7 were 
drawn using the complete data set including all observations. 
 
 
Figure 3.7 The relative Abundance of Lipids of Interest which Revert to the Healthy Level Upon 
Treatment. 
To identify lipids that are indicative of disease state and respond to TB treatment in mice, an animal 
experiment with three groups (healthy, infected, cured) was conducted. Blood was collected from all 
animals, lipids were extracted and the abundance of multiple specific ions were measured by mass 
spectrometry using an MRM based approach. Then, statistical tools were used to identify features 
(lipids) for which the mean of normalized intensities were not statistically different between samples of 
the non-diseased (healthy and cured) animals but were statistically different between the non-diseased 
versus diseased animals. Distributions of the observations for the lipids of interest were visualized by 
plotting scatter and error (+/- two standard error) plots. Three examples of these plots are shown here. 
An example of a lipid (796.9/184.1, PC 38:3p or 38:4e) for which the reverting trend was confirmed is 
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shown in A. However, for other features, the trend was not very clear (B; 832.7/745.7, PS 40:7) or 
appeared to heavily relay on extreme values (C; 770.9/184.1, 36:2p or 36:3e). 
 
A list of the features for which the trend of interest was confirmed by visual 
inspection, the lipid they represent and how they were regulated during infection is 
given in Table 3.2. 
Table 3.2 Features Identified as Showing the “Reverting” of Interest. 
Transition Lipid Regulation in Infection 
500.4 / 196.1 Lyso PE 20:4 down 
861.8 / 241.1 PI 36:2 up 
887.8 / 241.1 PI 38:3 up 
786.7 / 699.7 PS 36:2 up 
788.7 / 701.7 PS 36:1 up 
810.7 / 723.7 PS 38:4 up 
812.7 / 725.7 PS 38:3 up 
834.7 / 747.7 PS 40:6 up 
720.9 / 184.1 PC 32:0e up 
796.9 / 184.1 PC 38:3p, 38:4e up 
824.9 / 184.1 PC 40:3p, 40:4e up 
836.9 / 184.1 PC 40:5 up 
 
3.4. Detailed Characterization of Reverting Lipids 
Up to this point, all features could only be referred to as lipids belonging to a 
specific class and with a specified number of carbons atoms and double bonds in their 
acyl chains. We performed product ion scans for specific lipids to exactly determine 
chain length and saturation / unsaturation levels of fatty acids. In particular, 
fragmentation profiles of the features shown to exerting the reverting phenotype were 
acquired. As an example, the fragmentation profile of the ion with m/z ratio 786.4 is 
shown in Figure 3.8. In the current study the abundance of PS with this m/z ratios 
were measured by the transition 786.7 / 699.7. As confirmed by MS/MS, this 
transition represents PS 36:2 with a fatty acid composition of 18:1/18:1 or 18:0/18:2. 
This can be concluded from observing peaks corresponding to lysoPS 18:0, FA18:0, 
FA18:1 and FA18:2 in the fragmentation profile. 
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Figure 3.8 Fragmentation Spectra of Ion at m/z 786 
To investigate the fatty acid composition of lipids of interest, MS/MS was performed. The shown 
fragmentation spectrum is that of the ions with m/z 786.4. Based on the fragmentation of this ion and 
given the fact that it is scanned for in a PS type of transition (786.7/699.7), it can be concluded that this 
transition measures the lipid PS36:2 with the fatty acids (FA) 18:1/18:1 or 18:0/18:2. This is based on 
peaks corresponding to lysoPS 18:0, FA18:0, FA18:1 and FA18:2. The MS/MS pattern also indicates 
that the sample contains a PE with m/z ratio 786. Abbreviations: PS: phosphatidylserine, PA: 
phosphatidic acid, PE: phosphatidylethanolamine, GP: glycerol phosphate, FA: fatty acid, FA20:4-
CO2: FA20:4 with a CO2 lost, GPE: glycerolphosphate with ethanolamine, PE: ethanolamine and 
phosphate. 
 
In addition to the PS which was measured in the current study, the ion at m/z ratio 
of 786.4 also represents PE 40:8 with the fatty acid composition 20:4/20:4 or 
22:6/18:2. Finally with the fragmentation not limited exactly to the specified mass 
(786.4), the spectrum also contained daughter ions resulting from the fragmentation 
from an ion with m/z 788 (PE 40:7). However, the iosobaric PE 40:8 would not 
interfere with the MRM transition used to measure PS 36:2, since the latter scans for a 
neutral loss of 87, which limits the lipids that are detected to PS. In fact, the fragment 
with the m/z ratio of the ion that was used in Q3 of the transition (m/z 699.4) can also 
be observed in the product ion scan spectrum of PS 36:2 (see Figure 3.8). 
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After analyzing fragmentation profiles of the twelve ions of interest, peaks 
were assigned as far as possible. Each of the ions was found to represent a specific 
lipid or possible mixture of lipids of the same class with different combinations of 
FAs (see Table 3.3). MS/MS for PC was performed in the positive mode; therefore 
the exact FA composition of these measured ions could not be confirmed because FA 
do not ionize in the positive mode. However, it was possible to confirm that all of the 
ions represented a PC through the detection of the characteristic choline head group 
(m/z 184.1). 
Table 3.3 Characterization of Ions by MS/MM 
Transition Lipid FA composition 
500.4 / 196.1 Lyso PE 20:4 20:4 
861.8 / 241.1 PI 36:2 18:0/18:2 
887.8 / 241.1 PI 38:3 20:3/18:0 
786.7 / 699.7 PS 36:2 18:1/18:1 
18:0/18:2 
788.7 / 701.7 PS 36:1 18:1/18:0 
810.7 / 723.7 PS 38:4 20:4/18:0 
22:4/16:0 
812.7 / 725.7 PS 38:3 20:3/18:0 






   
 Lipid Head Group Confirmed 
720.9 / 184.1 PC 32:0e ✔ 
796.9 / 184.1 PC 38:3p, 38:4e ✔ 
824.9 / 184.1 PC 40:3p, 40:4e ✔ 
836.9 / 184.1 PC 40:5 ✔ 
 
3.5. Differences Between Diseased and Non-Diseased 
Furthermore we aimed at building a tool that can differentiate between non-
diseased (healthy or cured) and diseased (infected) animals. For this purpose, means 
of these two groups were statistically compared using both Student’s t-test and Mann 
Whitney U test (see Figure 3.9). 
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Figure 3.9 Significant Differences Between Lipid Profiles of Diseased and non-Diseased Animals 
Given one of the aims of this study to build a machine learning tool which can differentiate between 
the lipid profiles of diseased and non-diseased animal, the means of these two groups for all features 
were statistically compared; using Student’s t-test as well as Mann Whitney U test (MWU test). 
Furthermore, means from the data set with all observations as well as the one with the outliers replaced 
were compared. Based on the obtained p-values from the two tests, significance levels were colored as 
light gray for p-values <0.01, dark gray for <0.001 and black for Bonferroni corrected p-values <0.01. 
 
As shown in Figure 3.9, the means for several features differed statistically 
between samples from diseased and non-diseased mice. As above, results from the 
parametric and the non-parametric test were consistent in most of the cases, although 
there were slight differences. Outlier removal had only minor effects on the outcome 
of the two tests. The mean abundance of PS and PC were observed to be most often 
statistically different between the diseased and non-diseased states. Furthermore, 
features measured in the positive mode were found to differ statistically between the 
two groups more often than those of the negative mode. 
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Overall statistically significant differences between the lipid profiles of 
diseased and non-diseased animals could be observed, increasing the chance that a 
machine learning tool would be able to differentiate between the two groups. 
 
3.6. Support Vector Machines (SVM) Can Differentiate Between 
Diseased and non-Diseased Animals 
Given its ability to aid in proteomic and transcriptomics based cancer 
diagnosis, SVM was employed to build machine learning tools to differentiate 
between TB diseased and non-diseased mice. Such tools might eventually be used in 
pre-clinical TB drug efficacy trials. The current readout for these efficacy studies is 
the counting of CFU in the lungs of treated animals. The availability of a non-lethal 
blood based readout would greatly facilitate the development of novel TB drugs. 
Given the high dimensionality of our data set, feature reduction was required. 
Several approaches for feature reduction have been implemented in SVM (see 
Introduction) (Huang and Kecman, 2005). Here, we applied R-SVM to both data set 
(all observations and outliers replaced) (Zhang et al., 2006). 
Initially, the SVM cost parameter was optimized for both data sets. 
Independent of outlier replacement, cost was found to be optimal at C = 0.02. With 
this parameter fixed, the feature reduction was performed ranging from models with 
all 139 features to models with only two features only. The performances of the 
different computed models through the feature reduction are shown in Figure 3.10. 
Furthermore, the errors made by the models when predicting the training data set are 
also shown in Figure 3.10. The error in predicting the training set monitors over-
fitting. 
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Figure 3.10 R-SVM Parameter Optimization and Error During Feature Reduction 
The potential of a host lipid based biomarker for TB infection in pre-clinical mouse drug discovery 
studies was evaluated. For this purpose, an experiment with three groups of mice (healthy, infected, 
cured) was conducted, blood lipid extracted and analyzed by mass spectrometry. Using a recursive - 
support vector machine (R-SVM) based approach, models were trained to differentiate between 
diseased (infected) and non-diseased (healthy, cured) mice using the data set containing all 
observations (A) and the one with outliers replaced (B). The performance of the built models in cross 
validation throughout the feature reduction process are shown (solid line). Additionally, the error rate 
in predicting the training set was also monitored (dashed line). 
 
During the process of feature reduction it can be expected that the CV 
performance would be fairly constant, or even increase, as non-informative or 
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confounding features are being removed. However, at a certain point too many 
features get removed, true information is lost and the performance of the decreases 
model drastically. Both of these phases of feature reduction could be observed when 
R-SVM was applied to either of the two data sets (see Figure 3.10). For the data set 
with all observations, the decrease in CV performance was more gradual and a 
plateau was reached before the accuracies completely deteriorated. For the error in 
predicting the training set, it can be anticipated that it would be very low for models 
with a lot of features, indicating that it is potentially very specific to the data used and 
over-fitting may be occurring. This can be seen in Figure 3.10 by the fact that training 
set prediction error was 0%, whereas the accuracy of predicting an unknown sample 
did not exceed 95% for any of our models. Only as the number of features was 
reduced, especially when the number of features was less than the number of samples, 
did we observe an increase in the error of predicting the training set. To a certain 
extend, this increase could indicate that features with true information were removed 
and models with very high accuracies could no longer be trained. However, it likely 
indicated that the model became more general, as features which were overly specific 
to the training data set were removed. 
Nevertheless, selection of the best model is subjective. Here models were 
selected based on CV accuracy and self prediction error. We aimed at choosing SVM 
models with used the minimal amount of features without affecting the other two 
parameters too much. 
For the data set with outliers replaced, we selected the model with twelve 
features (accuracy: 88.6%; training set prediction error: 13.2%). It was selected based 
on its considerably high CV accuracy despite the low number of features needed. 
However, as seen in Figure 3.10, relaxing the restriction on the number of features 
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that should be used, the model with 46 features (92.1% accuracy) might also be worth 
considering. It is noteworthy that for the model using twelve features, accuracies of 
predicting the test and training set are very similar, indicating that the model was 
general and could be applied to unknown samples. The exact results of the CV for the 
model with twelve features are shown in Figure 3.11 and the list of the features used 
is given in Table 3.4. 
The best model including data from all observations incorporated ten features 
to differentiate between diseased and non-diseased animals (accuracy: 90.8%, training 
set prediction error: 9.2%). This model appeared to have less data over fitting, 
because it performed very well but included much less features as compared to other 
models. Interestingly, the model with all observations performed better than the ones 
with outliers replaced, indicating that outliers contained valuable information for the 
models. The exact CV results for the model with ten features are shown in Figure 
3.11, and the features selected are listed in Table 3.4. 
It is intriguing that models based on all observations and models based on the 
data set with the outliers replaced selected the same features for the prediction of 
diseased and non-diseased animals. Only two features were additionally incorporated 
into the model based on replaced outliers to increase its accuracy. In contrast, there 
were only one lipid, which appeared both in the list of features used by the machine 
learning tools as well as in the list of above identified lipid biomarker (see Table 3.2). 
In particular, several more lyso lipids were used by the machine learning tool Table 
3.4. 
Finally, the data set with all observations was also used to train two other 
machine learning tools (linear discriminate analysis and an emerging pattern based 
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classification), which both achieved high CV accuracies in differentiating between the 
three experimental groups (Li et al., 2007). Findings from these models indicated that 
differentiating between healthy and cured mice based on lipid profiles was more 
challenging than differentiating between either of these groups and the infected mice 
(personal communication Dr. Anja Gassner, IRMAC, Malaysia; and Dr. Guimei Liu, 
Lab of Dr. Limsoon Wong, School of Computing, NUS). 
 
 
Figure 3.11 SVM can Differentiate Between Disease and non-Disease Mice Based on Blood Lipid 
Profiles 
SVM differentiated between the blood lipid profiles of healthy and cured (‘non-diseased’) versus TB 
infected (‘diseased’) mice. The R-SVM code developed by Zhang et al. was used for feature reduction 
and cross validations (Zhang et al., 2006). For the data set with all observations the model using ten 
features was found to perform best using the leave-one-out cross validation (A). For the data set with 
the outliers replaced, a model with twelve features was determined to be best (B). Overall accuracy, 
sensitivity, specificity and the cross validation prediction results (confusion matrix) are shown. 
Table 3.4 Lipids Used to in Best Performing SVM 
Outlier Replaced All Data Lipid 
478.4/196.1 478.4/196.1 lyso PE 18:1 
857.7/241.1 857.7/241.1 PI 36:4 
861.8/241.1 861.8/241.1 PI 36:2 
885.8/241.1 885.8/241.1 PI 38:4 
887.8/241.1 887.8/241.1 PI 38:3 
496.6/184.1 496.6/184.1 lyso PC 16:0 
520.6/184.1 520.6/184.1 lyso PC 18:2 
544.6/184.1  lyso PC 20:4 
758.9/184.1 758.9/184.1 PC 34:2 
760.9/184.1 760.9/184.1 PC 34:1 
784.9/184.1  PC 36:3 
786.9/184.1 786.9/184.1 PC 36:2 
 






   58 
4.1. Technical Aspects of Lipid Biomarker Discovery 
Lipidomics is a fairly young discipline in which the methods and data analysis 
tools used are not yet standardized and different approaches are possible. Multiple 
experimental as well as data analytical aspects need to be considered when 
performing lipid based biomarker discovery.  
In particular the importance of keeping sample preparation and processing highly 
standardized has been emphasized (Sutphen et al., 2004; Wenk, 2005). In the current 
study two measures were taken to prevent the introduction of any systematic error: 
sample randomization and outlier replacement.  
The randomizing of the samples before processing and analysis will help to 
ensure that sample to sample differences are randomized across the experimental 
groups. This randomization becomes particularly important when handling a large 
number of samples which need to be processed and analyzed over several days. 
Especially, between instrument reproducibility for systems scale analysis has been 
questioned in the past (Couzin, 2006). However, a recent large scale multicenter study 
to evaluate the reproducibility of microarray data appears optimistic and found that 
the technology is more reliable than previously expected (Couzin, 2006). 
Nevertheless, for lipidomics these kinds of studies have not been performed and the 
consistence of lipid data across instruments and time remains to be shown.  
In this study, mock samples were included throughout the sample preparation and 
analysis. These samples were extraction from water and captured any measured signal 
not originating from lipids. For several MS measurements, a signal in the mock 
samples was identified, demonstrating the importance of using such negative control 
samples. 
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In addition to the practical considerations, the importance of performing careful 
data analysis has also been stressed in studies that aim at extracting biologically 
relevant information from large data sets (Wiest and Watkins, 2007). In the current 
study, the effect of outliers, data normalization, normality of data and issues relating 
to machine learning tools were evaluated. 
Outliers were identified based on Z-scores. Subsequently, it needed to be 
determined how they should be dealt with. We decided to create and analyze two data 
sets, one with all the original data points and one with the outliers being replaced. 
Outliers needed to be replaced as opposed to just removed due to the type of data 
normalization performed (see below). Our results show that outliers did not appear to 
affect the outcome of the data analysis. As a matter of fact, the support vector 
machines (SVM) were able to predict the differences between diseased and non-
diseased mice with higher accuracy when considering the complete data set. This 
indicates that the outliers may contain valuable information. However, whether this 
generally applies to outliers in MRM data sets still remains to be shown. Another way 
to deal with this problem could have been to remove the samples that contain many 
outliers. 
Another important issue in lipidomics data analysis is normalization of the MS 
data (Wiest and Watkins, 2007). In this study, lipid measurements were normalized to 
total ion counts. An alternative to this would be to normalize to internal standards. 
However, the MS signal from internal standards may suppress the signals from other 
lipids in the sample (personal communication Dr. Shui Guanghou). Nevertheless, a 
potential problem arising with the total ion count normalization used here is that this 
normalization causes the data to be correlated, which in turn can affect the outcome of 
the SVM (personal communication Dr. Anja Gassner, IRMAC, Malaysia). 
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In order to determine which statistical test to be used, we tested for normality of 
the data. We evaluated the raw as well as the normalized data, to identify features 
which strongly deviate from normality. This will provide detailed insights into the 
data and will facilitate the process of choosing the correct statistical tests. We found 
that most features measured in this study distribute normally. Nevertheless, we 
decided apply both, parametric as well as non-parametric tests, to identify differences 
between the lipid profiles of diseased and non-diseased animals. Most of our results 
were consistent with both tests, which supports the notion that parametric test are 
suitable to be applied on both normally and non-normally distributed data, as has been 
suggested previously (Lumley et al., 2002; Zar, 1999). Parametric tests, which 
compare their means of more than three groups, have the advantage over the non-
parametric equivalences that post hoc tests are available. These tests, such as the 
Tukey’s HSD test, exactly identify between which of the groups the differences exit 
(Zar, 1999). 
In the second aim of the current study, we set out to train machine learning tools 
to differentiate between diseased and non-diseased animals based on the lipid profiles. 
No matter which machine learning tool is used, issues such as cross validation, feature 
reduction, over fitting and the interpretability of the results, i.e. complexity of the 
computed models, all need to be considered (see also Introduction). 
In order to prevent over fitting of the machine learning tool, reduction of the 
features used to build the model is required. Of the many machine learning tools 
available, we decided to use recursive SVM (R-SVM), based on the fact that this tool 
has been reported to perform well for the analysis of complex biomedical data sets 
(Huang et al., 2006).  
   61 
Using an R-SVM approach on the data of the current study, we were able to build 
models that can differentiate with high accuracy between diseased and non-disease 
mice. By performing feature reduction and cross validation during the recursive 
process, the models deemed best have attributes such as less features than samples 
and a training data prediction error that is non-zero, which suggest that they have 
some power in predicting unknown samples. However, this would need to be 
confirmed on an independent data set (Huang et al., 2006). 
The list of lipids we identified as being important for machine learning is 
different from the list of biomarkers we identified using statistics. This difference can 
be attributed to the completely different approaches used by statistics and machine 
learning (Huang et al., 2006). One of these is the fact that the statistics used here are 
univariate, i.e. applied to each feature independently, whereas the machine learning 
approach is multivariate and considers all features at once. Furthermore, the feature 
reduction approach used in R-SVM is at least partially based on the mean difference 
between the two groups. This aspect of the data is not considered in the statistical 
approach used here. The correlation of the normalized data mentioned above may also 
explain some of the differences between the two lists. Given the complexity of SVM 
based models, the list of lipids identified through statistics was deemed more valuable 
here and thus only these were further interpreted. 
With regards to the complexity of SVM, alternatives machine learning tools 
should be considered. As a matter of fact, preliminary results using linear discriminate 
analysis showed that good separation between the groups and thus prediction of 
disease state can be achieved (see Results). 
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To develop robust prediction tools, the inclusion of even simple clinical data has 
been suggested to greatly improve the performance of models and should be seriously 
considered (Xie and Minna, 2008). 
 
4.2. Mechanistic considerations of Observed Changes in Lipids 
More sophisticated tools to study lipids have enhanced our understanding of 
their roles in several disease areas. It is known that they have important implications 
in viral as well as bacterial infections, atherosclerosis, inflammation, Alzheimer’s 
disease, metabolic disorders and cancer (van Meer et al., 2008; Wenk, 2005; Wymann 
and Schneiter, 2008). Additionally, they have been shown to be mediators of immune 
responses. Of particular interest to the current study is the role of lipids in processes 
that are involved in the host response to TB infections, such as inflammation. 
Briefly, as an immune response develops and affecter cells get activated, some 
of these cells experience massive increase in intracellular calcium, which causes the 
activation of multiple lipid related genes, e.g. cytosolic phospholipase A2 (cPLA2) 
and prostaglandin H2 synthase. The activation of cPLA2 leads to the release of 
arachidonic acid, a fatty acid (FA) with 20 carbon atoms and four double bonds, from 
phospholipids. The released FA in turn is the precursor for prostaglandins, 
leukotrienes and thromboxanes. These messenger molecules, which are collectively 
referred to as eicosanoids, promote classical features of inflammation, such as 
inducing pain and fever, and can act pro- as well as anti-inflammatory (Wymann and 
Schneiter, 2008). 
We hypothesized that, given the vast immune response of a host to TB 
infection, blood lipid profiles would be affected. By analyzing the lipid profiles of 
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blood from healthy, infected and cured animals, we were able to identify twelve lipids 
having the same relative abundance in healthy and cured animals, but increased or 
decreased levels in infected animals. Since rifampicin has been reported to have an 
influence on rat lipid profiles (Perrin et al., 2007), we were particularly interested in 
lipids which were the same in non-infected and drug treated animals, but did differ 
between the diseased and non-diseased groups. These lipids are indicators for disease 
state and not of host response to the drug. We refer to these lipids as ‘reverting’ lipids. 
Interestingly, we found that several phosphatidylserines (PS) and 
phosphatidylcholines (PC) showed the reverting trend described above. We also 
identified groups of closely related lipids which only differ by one double bond, 
which could imply biological relevance: if for example a particular pathway which 
connects those closely related lipids was affected by the TB infection, it would be 
expected that several lipids in this pathway respond in a similar fashion. Furthermore, 
there is ample evidence that PS is implicated in the host immune response to TB. This 
class of lipids has been shown to be exported to the cell surface during apoptosis (Wu 
et al., 2006). This process of programmed cell death is increased during TB infection 
and causes a two-fold increase in PS production (Lopez et al., 2003; Perskvist et al., 
2002; Vance, 2008). PC on the other hand has been suggested to potentially play a 
role in the balance between pro- and anti-inflammatory responses during TB infection 
(Treede et al., 2007). These implications of PS and PC in the anti-TB immune 
response may explain why these lipid were identified here. 
In agreement with the discussed involvement of arachidonic acid (AA) in 
inflammatory processes, we detected reduced level of AA containing lyso PE in 
infected animals. This might indicate a role of AA release during TB infection. 
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4.3. Value of Developed Method in Drug Discovery 
In TB drug discovery, mouse models are most commonly used to evaluate 
potential novel drugs. This evaluation is most often done by counting CFU in the 
lungs of the animals. It has recently been suggested that additional features such as 
damage to the lungs and the immune state of the animals should be considered. It is 
expected that these read-outs would provide additional information on the rate of 
bacterial clearance as well as the relapse rate (Lenaerts et al., 2008). 
 Here we set out to identify lipid biomarkers of TB infection which revert to 
the healthy level upon successful drug treatment, and to build machine learning tools 
that can differentiate between TB diseased and non-diseased animals. Given the 
substantial involvement of lipids in the TB immune response we hypothesize that the 
lipids identified here may actually reflect the immune status of the animals (see 
above). Further studies analyzing the immune response, e.g. by interferon gamma 
release assay, are needed to complement the findings of this study. 
Furthermore, the specificity of the response to TB infection would need to be 
further investigated. Applying a proteomics approach, markers that appear to be TB 
specific were identified in human patients (Agranoff et al., 2006). Within the well 
defined conditions of pre-clinical drug testing in an animal model though, this disease 
specificity is not required since animals will only be infected with a single disease. 
However, the effect of any drug alone on a potential host based marker needs 
to be considered. Most importantly for the current study, rifampicin has been shown 
to effect the lipid profile of rats (Pal et al., 2008). In a current follow-up study, a 
fourth group of uninfected but rifampicin treated animals has been included. This 
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control group will help to differentiate between the host response to the drug itself 
and to the combined effect of infection and drug treatment. 
 
4.4. Conclusion 
With the global re-emergence of tuberculosis (TB), the need for novel drugs is 
pressing. 
Here we developed an analytical approach based on the analysis of host lipid 
profiles. Whole blood lipids of healthy, TB-infected and TB-infected and drug-
treated, i.e. cured, mice were quantified by mass spectrometry. Employing classical 
statistics, a set of twelve lipid species was identified as possible biomarkers for the 
disease state of the animals. Subsequently, support vector machines were trained, 
optimized and shown to discriminate between the diseased and non-diseased animals 
with high accuracy.  
Taking a broader view, this new approach can be potentially applied to identify 
lipid biomarkers of drug response in pre-clinical studies. 
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6.1. Data Analysis Using R 
6.1.1. R script to Asses Normality: 
# R_normality version: 13.11.2008 
# This script will allow you to compute p-values for the Shapiro-Wilk test. 
# 
# Data should have features (e.g. relative abundance of lipids measured) arranged vertically (i.e. 
in columns) and samples horizontally (i.e. in rows). 
# 
# Steps: 
# 1. Make the following changes: start.column (column of first feature); end.column (column of 
last feature); start.row and end.row (fisrt and last row of data to be included for 
computation of normality test) 
# 2. Copy / past entire script into R command line. 
# 3. To run the script type narmality(inputfile, outputfile, test): inputfile: name off data file; 
outputfile: name of the file you want the output to be saved in also in “” and with .csv 
extension; test: shapiro.test (for the Shapiro-Wilk test) 
# 
# HERE IS THE SCRIPT: 
normality<-function(inputfile, outputfile, test){ 
b<-(read.csv(inputfile, header=T)) 




write(c(i, d), file=outputfile, ncolumn=2, append=T, sep=",") 
} 
print("It is done.") 
} 
 
6.1.2. R Script to Perform R-SVM. 
 For simplicity and because this script requires multiple steps it is arranged 
differently then the one. The code is rearranged and slightly modified from Zhang et 
al., 2006 by MWB and Li Bowen. 
Step 1. Ensure that the R package e1071 is installed. It can be installed by using the 
following command and following the instructions. 
 install.packages(“e1071”) 
Step 2. Save your data file as CSV and the script in the next box as TXT (for example 
as R-SVM_script.txt) in a new folder. Data should be arranged with class label (1 and 
-1) in the first column, lipid measurements in the following columns and the top row 
as header (e.g. class, lipid1, lipid2, …). 
### R-code for R-SVM 
### use leave-one-out / Nfold or bootstrape to permute data for external CV 
### build SVM model and use mean-balanced weight to sort genes on training set 
### and recursive elimination of least important genes 
### author: Dr. Xin Lu, Research Scientist 
###   Biostatistics Department, Harvard School of Public Health 
library(e1071) 
## wrapper function 
## simple cross validation  
SVMCV <- function(x,y,CVtype,CVnum=0){ 
## check if y is binary response 
Ytype <- names(table(y)) 
if( length(Ytype) != 2)  
{ 
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print("ERROR!! RSVM can only deal with 2-class problem") 
return(0) 
} 
nSample <- nrow(x) 
nGene   <- ncol(x) 
SampInd <- seq(1, nSample) 
if( CVtype == "LOO" ) 
{ 
CVnum <- nSample 
} else 
{ 
if( CVnum == 0 ) 
{ 
CVnum <- nSample 
} 
} 
## vector for test error and number of tests 
ErrTrain <- 0 
ErrTest <- 0 
nTrain <- 0 
nTest <- 0 
 
for( i in 1:CVnum ) 
{ 
## split data 
if( CVtype == "LOO" ) 
{ 
TestInd <- i 
TrainInd <- SampInd[ -TestInd] 
} else 
{ 
if( CVtype == "bootstrape" ) 
{ 
TrainInd <- sample(SampInd, nSample, replace=T ) 




TrainInd <- sample(SampInd, nSample*(CVtype-1)/CVtype ) 
TestInd <- SampInd[ which(!(SampInd %in% TrainInd ))] 
} 
} 
nTrain <- nTrain + length(TrainInd) 
 nTest <- nTest + length(TestInd) 
## in each level, train a SVM model and record test error 
xTrain <- x[TrainInd, ] 
yTrain <- y[TrainInd] 
xTest  <- x[TestInd,] 
yTest  <- y[TestInd] 
 model <- svm(xTrain,yTrain,type="C-classification",kernel="linear",cost = 1) 
 predictTrain <- predict(model,xTrain) 
 predictTest <- predict(model,xTest) 
 ErrTrain <- ErrTrain + sum(predictTrain != yTrain) 
 ErrTest <- ErrTest + sum(predictTest != yTest) 
} 
ret <- list(Error1 = ErrTest/nTest,Error2 = ErrTrain/nTrain, nTest = nTest, nTrain = nTrain) 
} 
## wrapper function 
## avoid passing arguments from Matlab to R many times 
RSVM_wrapper <- function(filename, pRatio, Nmin, CVtype, scaler=1) 
{ 
 data <- ReadSVMdata(filename) 
 Ntotal <- dim(x)[2] 
 ladder <- CreatLadder(Ntotal, pRatio, Nmin) 
 if (scaler <= 0 ){ 
  scaler = 1 
 } 
 if (scaler != 1){ 
  model <- RSVM(scaler*data$x,data$y,ladder,CVtype) 
 }else{ 




## read in SVM formated data in filename 
## the format following the defination of SVMTorch 
## the first line contains 2 integer: nSample  nFeature+1  
## followed by a matrix, each row for one sample, with the last column being +/1 1 for class label 
ReadSVMdata <- function(filename) 
{ 
dd <- read.csv( filename, header=T, sep="\t") 
x <- as.matrix( dd[, 2:ncol(dd)] )  
y <- factor( dd[, 1] ) 
ret <- list(x=x, y=y) 
} 
## create a decreasing ladder for recursive feature elimination 
CreatLadder <- function( Ntotal, pRatio=0.75, Nmin=5 ) 
{ 
x <- vector() 
x[1] <- Ntotal 
for( i in 1:100 ) 
{ 
pp <- round(x[i] * pRatio) 
if( pp == x[i] ) 
{ 
pp <- pp-1 
}           
if( pp >= Nmin ) 
{ 






    x 
} 
## R-SVM core code 
## input: 
##    x: row matrix of data 
##    y: class label: 1 / -1 for 2 classes 
##    CVtype:  
##        integer: N fold CV 
##        "LOO":    leave-one-out CV 
##        "bootstrape": bootstrape CV 
##    CVnum:   number of CVs 
##        LOO: defined as sample size 
##        Nfold and bootstrape:  user defined, default as sample size 
## output: a named list 
##    Error: a vector of CV error on each level 
##    SelFreq: a matrix for the frequency of each gene being selected in each level 
##             with each column corresponds to a level of selection 
##             and each row for a gene 
##          The top important gene in each level are those high-freqent ones 
RSVM <- function(x, y, ladder, CVtype, CVnum=0) 
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{ 
## check if y is binary response 
Ytype <- names(table(y)) 
if( length(Ytype) != 2)  
{ 
print("ERROR!! RSVM can only deal with 2-class problem") 
return(0) 
} 
## class mean 
m1 <- apply(x[ which(y==Ytype[1]), ], 2, mean) 
m2 <- apply(x[ which(y==Ytype[2]), ], 2, mean) 
md <- m1-m2 
yy <- vector( length=length(y)) 
yy[which(y==Ytype[1])] <- 1 
yy[which(y==Ytype[2])] <- -1         
y <- yy 
## check ladder 
if( min(diff(ladder)) >= 0 ) 
{ 
print("ERROR!! ladder must be monotonously decreasing") 
return(0); 
} 
if( ladder[1] != ncol(x) ) 
{ 
ladder <- c(ncol(x), ladder) 
} 
nSample <- nrow(x) 
nGene   <- ncol(x) 
SampInd <- seq(1, nSample) 
if( CVtype == "LOO" ) 
{ 
CVnum <- nSample 
} else 
{ 
if( CVnum == 0 ) 
{ 
CVnum <- nSample 
} 
} 
## vector for test error and number of tests 
ErrVec <- vector( length=length(ladder)) 
Err <- vector( length=length(ladder)) 
names(ErrVec) <- paste("Lev_", ladder, sep="") 
names(Err) <- paste("Lev_", ladder, sep="") 
nTests <- 0 
ErrTests <-0 
SelFreq <- matrix( 0, nrow=nGene, ncol=length(ladder)) 
colnames(SelFreq) <- paste("Lev_", ladder, sep="") 
# matrix for accuracy in each CV and ladder 
CVXladder <- matrix(0, nrow=CVnum, ncol=length(ladder)) 
colnames(CVXladder) <- paste("Lev_", ladder, sep="") 
# matrix for confusion table 
confuMatrix <- matrix(0, nrow=4, ncol=length(ladder)) 
colnames(confuMatrix) <- paste("Lev_", ladder ,sep="") 
## for each CV     
for( i in 1:CVnum ) 
{ 
## split data 
if( CVtype == "LOO" ) 
{ 
TestInd <- i 
TrainInd <- SampInd[ -TestInd] 
} else 
{ 
if( CVtype == "bootstrape" ) 
{ 
TrainInd <- sample(SampInd, nSample, replace=T ) 




TrainInd <- sample(SampInd, nSample*(CVtype-1)/CVtype ) 
TestInd <- SampInd[ which(!(SampInd %in% TrainInd ))] 
} 
} 
nTests <- nTests + length(TestInd) 
 ErrTests <- ErrTests + length(TrainInd) 
## in each level, train a SVM model and record test error 
xTrain <- x[TrainInd, ] 
yTrain <- y[TrainInd] 
xTest  <- x[TestInd,] 
yTest  <- y[TestInd] 
## index of the genes used in the  
SelInd <- seq(1, nGene) 
 for( gLevel in 1:length(ladder) ) 
{ 
## record the genes selected in this ladder 
SelFreq[SelInd, gLevel] <- SelFreq[SelInd, gLevel] +1 
## train SVM model and test error 
svmres <- svm(xTrain[, SelInd], yTrain, scale=F, type="C-classification", kernel="linear",cost=0.02) 
if( CVtype == "LOO" ) 
{ 
svmpred <- predict(svmres, matrix(xTest[SelInd], nrow=1) ) 
          errpred <- predict(svmres, xTrain[,SelInd]) 
} else 
{ 
svmpred <- predict(svmres, xTest[, SelInd] ) 
   errpred <- predict(svmres, xTrain[,SelInd]) 
} 
ErrVec[gLevel] <- ErrVec[gLevel] + sum(svmpred != yTest ) 
Err[gLevel] <- Err[gLevel] + sum(errpred != yTrain) 
      # update confuMatrix and CVXladder 
      CVXladder[i,gLevel] <- sum(svmpred != yTest) / length(yTest) 
      for( k in 1:length(yTest)) 
      { 
  if ( svmpred[k] == 1 && yTest[k] == 1) 
  {# True positive 
   ind = 1 
  }else if( svmpred[k] == 1 && yTest[k] == -1) 
  {# False positive 
   ind = 2 
  }else if( svmpred[k] == -1 && yTest[k] == 1) 
  {# Fals negative 
   ind = 3 
  }else if( svmpred[k] == -1 && yTest[k] == -1) 
  {# True negative 
   ind = 4 
  } 
  confuMatrix[ind,gLevel] <- confuMatrix[ind,gLevel] + 1 
      } 
## weight vector 
W <- t(svmres$coefs*yTrain[svmres$index]) %*% svmres$SV * md[SelInd] 
rkW <- rank(W) 
if( gLevel < length(ladder) ) 
{ 
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SelInd <- SelInd[which(rkW > (ladder[gLevel] - ladder[gLevel+1]))] 
} 
}# ladder loop 
}# CV loop 
ret <- list(ladder=ladder, Error=ErrVec/nTests, Error2=Err/ErrTests, SelFreq=SelFreq, CVXladder=CVXladder, 
confuMatrix=confuMatrix) 
} 
SummaryRSVM <- function( RSVMres ) 
{ 
ERInd <- max( which(RSVMres$Error == min(RSVMres$Error)) ) 
MinLevel <- RSVMres$ladder[ERInd] 
FreqVec <- RSVMres$SelFreq[, ERInd] 
SelInd <- which( rank(FreqVec) >= (ladder[1]-MinLevel) ) 
#print("MinCV error of", min(RSVMres$Error), "at", MinLevel, "genes" ) 





Step 3. Set the working directory to the newly created folder. Then use the following 
command to link R to the file with the R-SVM script. 
 source("R-SVM_script.txt") 
Step 4. The following commands, with modifications, will enter the data into R. The 
ladder command will create a string of numbers that specify the number of lipids to 
be included in each step of feature reduction. Modifications: file.name (name of your 
data file with .csv extension); Ntotal (total number of lipids measured); pRatio 
(percent of lipids to be included in next step of feature reduction, e.g. 0.75); Nmin 




 ladder<-CreatLadder(Ntotal, pRatio, Nmin) 
Step 5 (Optional). This step will tune the cost parameters of SVM. In the example 
given the cost parameter is optimized from 2x10-6 to 2x106. Default cost = 1 can be 
used. The output of the optimization will be printed, and the necessary changes in the 
R-SVM code can be made. If changes are made, Step 3 will need to be repeated. 
 obj<-tune.svm(x,y,cost=2*10^(-6:6) ,kernel="linear") 
 obj 
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Step 6. R-SVM can now be run using the given command.  
 model<-RSVM(x,y,ladder,"LOO") 
After R has finished the operation, the following outputs are of interest: 
model$Error (the error in during cross validation at each ladder position) 
model$Error2 (the self prediction error, i.e. error in predicting the training data set) 
model$SelFreq (which features get selected over the course of feature reduction) 
 
 
 
 
 
 
